Viking says every-other-week VK2735 holds up to 97% of weight loss
Monthly dosing retained up to 90% of prior loss over 12 weeks; Viking shares closed 35.7% higher at $40.85.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 22 11:12 ETSource: WTVB
The wire
- 01After a 21-week induction, patients switched to every-other-week VK2735 maintained up to 97% of lost weight, while monthly dosing retained up to 90% over the following 12 weeks.
- 02Less frequent maintenance dosing could affect persistence on obesity drugs, a live question for prescribers and telehealth programs managing long-term incretin therapy.
- 03A small group treated weekly for 33 weeks lost an average 21.7% of body weight; Viking says it plans to study oral maintenance dosing later in the trial.
From the source
Read at wtvbam.comViking Therapeutics’ obesity drug shows durable weight-loss benefit, shares surge
Sept 22 (Reuters) – Viking Therapeutics on Tuesday said patients shifted to a less frequent dosing regimen of its experimental obesity treatment showed superior weight-loss maintenance in a study compared with those on placebo.
